Celldex Therapeutics Inc. (CLDX) News
Filter CLDX News Items
CLDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLDX News Highlights
- For CLDX, its 30 day story count is now at 2.
- Over the past 9 days, the trend for CLDX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MRTX and NOV are the most mentioned tickers in articles about CLDX.
Latest CLDX News From Around the Web
Below are the latest news stories about CELLDEX THERAPEUTICS INC that investors may wish to consider to help them evaluate CLDX as an investment opportunity.
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx ConferenceHAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th at 5:05 pm ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a |
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining HealthcareThe article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms. |
Celldex Therapeutics Announces Pricing of Public Offering of Common StockHAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,113,750 shares of common stock at the public offering price, less underwriting discounts and commissions. Jef |
Celldex Therapeutics Announces Proposed Public Offering of Common StockHAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by the Company. Celldex |
Why Celldex Therapeutics Blasted 13% Higher on MondayClinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) was a standout on the stock market Monday. The company's share price closed a sturdy 13% higher on the day, thanks to freshly published data from a clinical trial of a key pipeline drug. The biotech reported that barzolvolimab achieved its primary efficacy endpoint in treating this form of urticaria (more commonly known as hives). |
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, SanofiCelldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies. |
Celldex’s reinvention advances with inflammatory disease drug dataShares in the biotech jumped higher Monday on positive results for the company's drug barzolvolimab in two chronic itching conditions. |
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups--Mean change from baseline to week 12 in UAS7 of -23.87 in 300 mg q8w dose group and -23.02 in 150 mg q4w dose group--Barzolvolimab was generally well tolerated with a favorable safety profile--Treatment will continue to 52 weeks; results support further development of barzolvolimab in Phase 3 CSU studies-- Company to host webcast call t |
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab- Response observed as early as week 1 and durable for up to 16 weeks -- Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications -- Phase 2 PN study to initiate in early 2024 -- Conference call to be held on Monday, November 6th at 8:00 am ET to discuss study results - HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in pruri |